Scinai director reports initial SCNI holdings

Scinai Immunotherapeutics Ltd. director Samuel J. Moed filed an initial ownership report showing existing equity interests.

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. director Samuel J. Moed filed an initial ownership report showing existing equity interests. He holds 50 American Depositary Shares convertible into 200,000 Ordinary Shares at any time with no expiration date, plus stock options over 4,000,000, 8,000,000 and 48,200,000 Ordinary Shares at exercise prices of $0.0050 and $0.0004 per share. These options vest in annual installments beginning on August 24, 2024, August 24, 2027 and December 22, 2026, contingent on his continued service, and expire between 2033 and 2035.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Moed Samuel J

Role Director

Type	Security	Shares	Price	Value
holding	American Depositary Shares	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--

Holdings After Transaction: American Depositary Shares — 200,000 contracts (Direct); Stock Option (right to buy) — 60,200,000 contracts (Direct)

Footnotes (5)

1. F1. Represents 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares, at the holder's election and have no expiration date.
2. F2. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.
3. F3. The option vests in one installment on August 24, 2027, subject to the Reporting Person's continued service through such date.
4. F4. The option vests in three equal annual installments commencing August 24, 2024, subject to the Reporting Person's continued service through such dates.
5. F5. The option vests in three equal annual installments commencing December 22, 2026, subject to the Reporting Person's continued service through such dates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing show for Scinai Immunotherapeutics (SCNI)?

The Form 3 shows director Samuel J. Moed’s existing equity holdings in Scinai Immunotherapeutics. It lists American Depositary Shares and several stock option grants over Ordinary Shares, along with exercise prices, vesting schedules, and expiration dates.

How many American Depositary Shares does the SCNI director report holding?

Samuel J. Moed reports holding 50 American Depositary Shares. According to the filing, these are convertible at any time into 200,000 Ordinary Shares and have no expiration date, giving him direct exposure to the company’s Ordinary Shares.

What stock options over Ordinary Shares does the SCNI director hold?

The director holds stock options over 4,000,000, 8,000,000 and 48,200,000 Ordinary Shares. Exercise prices are $0.0050 for the 4,000,000 and 8,000,000 share options, and $0.0004 for the 48,200,000 share option, with expirations in 2033 and 2035.

When do the SCNI director’s stock options begin vesting?

The options vest in installments starting on August 24, 2024, August 24, 2027 and December 22, 2026. Vesting is subject to the director’s continued service through the relevant dates, which is typical for long-term incentive awards.

What is the ADS to Ordinary Share ratio for Scinai Immunotherapeutics (SCNI)?

Each American Depositary Share currently represents 4,000 Ordinary Shares. The filing notes that 50 ADSs are convertible into 200,000 Ordinary Shares, confirming the 1-to-4,000 ratio for Scinai Immunotherapeutics’ ADS program.

Does the Form 3 for SCNI show any recent insider buying or selling?

The Form 3 is an initial ownership report and lists holdings rather than recent trades. The summarized data show existing American Depositary Shares and option awards, with no explicit buy or sell transactions indicated in the provided information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 10:05 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Moed Samuel J

(Last) (First) (Middle)

C/O SCINAI IMMUNOTHERAPEUTICS LTD.

JERUSALEM BIOPARK, 2ND FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Scinai Immunotherapeutics Ltd. [ SCNI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(1)	(1)	Ordinary shares, no par value per share ("Ordinary Shares")(2)	200,000	(1)	D
Stock Option (right to buy)	(3)	08/24/2033	Ordinary Shares	4,000,000	$0.005	D
Stock Option (right to buy)	(4)	08/24/2033	Ordinary Shares	8,000,000	$0.005	D
Stock Option (right to buy)	(5)	12/22/2035	Ordinary Shares	48,200,000	$0.0004	D

Explanation of Responses:

1. Represents 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares, at the holder's election and have no expiration date.

2. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

3. The option vests in one installment on August 24, 2027, subject to the Reporting Person's continued service through such date.

4. The option vests in three equal annual installments commencing August 24, 2024, subject to the Reporting Person's continued service through such dates.

5. The option vests in three equal annual installments commencing December 22, 2026, subject to the Reporting Person's continued service through such dates.

Remarks:

Exhibit 24 - Power of Attorney.

	/s/ Amir Reichman, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)